4Potentia

4Potentia is a pre-clinical stage biotechnology company dedicated to developing a new class of immunotherapies designed to potentiate the immune system's ability to combat cancer. Founded by renowned Stanford University professors Peter S. Kim and Jennifer Cochran, the company utilizes advanced protein engineering and directed evolution to create novel biologics. Its primary focus is on the CD47-SIRPα 'don't eat me' signaling pathway, with the goal of developing therapies that offer superior efficacy and safety compared to first-generation inhibitors. Headquartered in Menlo Park, California, 4Potentia is backed by leading venture capital firms, including Sutter Hill Ventures and Lightspeed Venture Partners. The company's pipeline currently includes several programs targeting solid tumors and hematological malignancies.